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Background: Biological evidence reported in the literature supports the role of CELSR1 as being essential for
valvular function in murine lymphatics. Yet thus far, there have been no variants in CELSR1 associated with
lymphatic dysfunction in humans.
Case Presentation: In this report, a rare early inactivating mutation in CELSR1 is found to be causal for non-
syndromic, lower extremity lymphedema in a family across three generations. Near-infrared fluorescence lymphatic
imaging shows that instead of being propelled within the lumen of well-defined lymphatic vessels, lymph moved
in regions of both legs in an unusual fashion and within sheet-like structures.
Conclusion: CELSRI may be responsible for primary, non-syndromic lymphedema in humans.
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Lymphedema (LE) is a condition caused by a defective
lymphatic system where an excess of fluid accumulates
and generates chronic swelling of tissues. Primary LE is a
rare genetic disorder that can develop at birth (congeni-
tal), at puberty (praecox), or after 35 years of age (tarda)
[1]. FLT4 was the first pathogenic gene identified in
primary LE [2], but to date, there is only a handful of
genes (FOXC2, CCBE1, GCJ2, SOX18, GATA2, PTPN14)
associated with hereditary LE, with the majority associated
with patients in which LE is part of a genetic syndrome
[3]. Mendola et al. recently argued that the genetic
cause(s) of the majority of families harboring hereditary
LE has not yet been identified. In their group of 78 index
patients with inherited LE who were screened for muta-
tions in the top seven LE genes, they found explanations
for only 36 % of the cases [4].
In this report, we present the unusual lymphatic pheno-
type obtained by near-infrared fluorescence lymphatic im-
aging (NIRFLI) of a woman diagnosed non-syndromic,
lower extremity LE and compare it with that of her* Correspondence: eva.sevick@uth.tmc.edu
1Center for Molecular Imaging, The Brown Foundation Institute of Molecular
Medicine, The University of Texas Health Science Center, 1825 Pressler Street,
SRB330A, Houston, TX 77030, USA
Full list of author information is available at the end of the article
© 2016 Gonzalez-Garay et al. Open Access Th
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeasymptomatic mother. From clinical diagnoses and whole
exome sequencing (WES) of family members across three
generations, we found no gene variants known to be
responsible for LE, but instead found a rare, inactivating
mutation in CELSR1 that could be causative for the inher-




A 62 yo female previously diagnosed with primary, lower
extremity LE (bilateral, Stage II by International Society
of Lymphology staging system) and her 84 yo asymp-
tomatic mother enrolled in an ongoing, institutional
review board (IRB) and FDA-approved (IND# 102,827)
clinical study of lymphatic disorders (Clinical Trials No.
NCT00833599: “Imaging lymphatic function in normal
subjects and in persons with lymphatic disorders”
www.clinicaltrials.gov). The index case self-reported on-
set of lower extremity swelling at age 10, with diagnosis
of LE at age 39 at which time she began compression
treatment. In addition, she was also previously diagnosed
with type 2 diabetes, high cholesterol, and high blood
pressure. Following consent, a clinical examination was
first performed followed by near-infrared fluorescence
lymphatic imaging (NIRFLI) [5] to assess lymphaticis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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for WES of DNA.
Upon questioning, we further found a family history of
lower extremity LE and traveled to the family’s hometown
to consent, conduct standard clinical examinations (includ-
ing measurements of leg volumes and assessment of
Stemmer’s sign), and to collect blood from family members
spanning three generations. We did not perform NIRFLI
on these family members. Other than stage I and II bilat-
eral lower extremity, non-syndromic LE, we found no re-
markable evidence of disease among the family members.
Imaging studies
For lymphatic imaging of the daughter and mother,
doses of 25 μg of indocyanine green (ICG) in 0.1 cc sa-
line were administered bilaterally in the dorsum of the
feet, medial ankles, the medial and lateral calves, and the
thighs for a total dose of 300 μg. Images were acquired
with exposure times of 200 ms and sequential images
were compiled to assess for the presence of active
lymphatic propulsion/movement of ICG-laden lymph
from the injection sites proximally towards the inguinal
lymph node basins. As shown by NIRFLI in Fig. 1b, the
affected daughter had extensive areas of dermal backflow
in her lower legs, as commonly observed in LE subjects,
but possessed a unique, uncommon flow pattern of
lymph movement that appeared in “sheets” rather than
within distinct vessel lumens (Additional file 1: Video 1).
While the proband’s mother primarily had well-defined
and linear lymphatics (Fig. 1b) as typically seen in healthy
subjects [6, 7], she nonetheless presented with smallerFig. 1 Montages of NIRFLI of the lower extremities of (a) the proband and
also had areas with dermal backflow as shown in the inset images of (b)areas of dermal backflow and tortuous lymphatics as
shown in the insets of Fig. 1b. Active lymphatic propulsion
of ICG-laden lymph was observed in the well-defined
lymphatic vessels in the mother (Additional file 2: Video 2),
in contrast to the limited lymphatic movement observed in
the daughter.
Family evaluation
In addition to the proband and her mother, DNA was
collected from 9 family members (subjects 146-154) in-
cluding 5 members diagnosed with LE upon clinical
examination. The pedigree chart in Fig. 2 shows that the
diagnosed disorder segregates in an autosomal dominant
manner. The affected members exhibited grade II bilat-
eral leg lymphedema, with the exception of subject 154,
with grade I bilateral leg lymphedema. DNA was ex-
tracted from blood samples using Paxgene Blood DNA
Kit (PreAnalytix, Switzerland) according to the vendor's
instructions. 2 μg of genomic DNA was submitted to
Axeq Technologies for human exome capture sequen-
cing using SureSelect Human All Exon V5 and V5 +
UTRs (Agilent Technology, Santa Clara, CA).
Genetic sequencing analyses
Genetic sequencing analysis was conducted as follows.
Each pair of fastq files was aligned to human genome
(hg19) using Novoalign (Novocraft Technologies;
www.novocraft.com), keeping parameters at the de-
fault settings, as recommended by Novocraft Tech-
nologies. SAMtools (http://samtools.sourceforge.net)
was used to sort the SAM files, create BAM files, and(b) her mother. While the mother had well-defined lymphatics, she
Fig. 2 Pedigree of the family showing members diagnosed with lymphedema (filled black), unknown phenotype (filled gray) and unaffected
(open) subjects. Arrow indicates the proband. The small ‘s’ at the left top corner of the subjects indicates when the subject’s DNA was
sequenced. A diagonal line indicates that the patient is deceased
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broadinstitute.github.io/picard) was used to remove all
of the PCR duplicates from the BAM files. For local
realignments, base quality recalibration, and variant
calling, we used Genome Analysis Toolkit (GATK)
Version 3.1-1 [8]. Finally, for variant annotation, we
used SnpEff (http://snpeff.sourceforge.net/) [9], variant
tools and ANNOVAR [10] using multiple databases
from UCSC Genome bioinformatics. Functional ef-
fects for each non-synonymous coding variant was
evaluated using three different functional prediction
algorithms: (1) Polyphen 2.0 Prediction of functional
effects of human nsSNPs (http://genetics.bwh.harvar-
d.edu/pph2) [11], (2) SIFT [12] and (3) (www.muta-
tiontaster.org) [13] using the dbNSFP database [14].
Filtration of common polymorphisms was accom-
plished using frequencies from the NHLBI Exome se-
quencing project (ESP) (http://evs.gs.washington.edu/
EVS) [15] and the 1,000 Genomes Project (http://
www.1000genomes.org/data) [16].
WES results showed that the proband did not have
variants in any of the known genes previously associated
with lymphatic dysfunction. To maximize the power of
the segregation analysis, we selected family members
diagnosed with LE from each generation for a total of 5
affected cases. Since we did not have controls of the
same ethnicity, we selected 4 unaffected family members
to reduce the background and increase the statistical
power of the analysis. The raw results from the sequen-
cing passed our standard quality control, and the variant
files (vcf ) reported a consistent number of variants.
After selecting non-synonymous coding variants with
low frequency (MAF < 0.1), we performed co-segregation
analysis using a dominant model of inheritance. Our
analysis generated six potential candidate variants, five
of them were eliminated after a quick manual inspec-
tion with the Integrative genomics viewer [17]. Weidentified a nonsense coding variant that generated a
prematurely terminated protein CELSR1 (p.W1957X,
Hg19chr22:g.46,790,132C > T; NC_000022.10:g.467901
432C > T; NM_014246.1:c.5871G > A). The variant was
private to the family and has not been reported in
any of the following databases: 1000 Genomes [16],
ESP6500 [15],UK10K, TCGA germline [18], Scripps
Wellderly [19], ExAC [20], dbNSFP [14], ClinVar [21],
OMIM [22], COSMIC [23], and Reference Variant
Store (RVS), [24]. The variant sequence was of high qual-
ity with an average of 108.54 ± 20.93 reads per sample,
mapping quality > 70, and Phred quality scores > 35. Fur-
thermore, the variant was confirmed in each sample by
Sanger sequencing in the forward direction using primer
TGAGGTTGGGAGCCGGTAGAGG and the reverse
direction using primer GTACCGACAGGGTATGTGAA
GGCG (see Additional file 3: Figure S1). The segregation
results were perfect, the variant was present in all the
affected and was not present in any of the unaffected. We
genotyped two additional unaffected members of the fam-
ily, and they also lacked the variant. We searched using
blat a 90 bp region containing the mutation against the
human reference hg19 and found that the region was
100 % unique in the human genome. We also found that
the same region was totally free of any repeats and evolu-
tionarily conserved in vertebrates according to the com-
parative genomics track from the UCSC genome browser
[25]. In summary, the ultra-rare damaging variant was
present in five affected members and not present in six un-
affected family members (Fig. 3a). From DNA of the family
members sampled, there appears to be 100 % penetrance
with an autosomal dominant pattern of inheritance.
Discussion
CELSR1 is a member of the cadherin superfamily, con-
served during evolution with orthologs in invertebrate
and vertebrates [26]. In addition, CELSR1 is an atypical
Fig. 3 a Image from the Integrative genomics viewer, showing a 40 bp genomic region containing the variant. Each one of the samples is
loaded into the panel. Each panel shows two windows, the top window displays the number of reads, and the allele fraction and the lower
window show the alignments of the experimental reads. The bottom panel displays the transcripts with the open reading frames. b A cartoon
representing the predicted protein structure of CELSR1 (uniprot id Q9NYQ6). An arrow represents the location of the mutation. The cartoon was
inspired by the publication of Lei, et al., 2014 [30]
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has nine cadherin repeats, eight EGF-like domains, and
seven transmembrane segments (Uniprot_id Q9NYQ6).
CELSR1 is located at the plasma membrane with the
cadherin domains acting as homophilic binding regions
and the EGF-like domains involved in cell adhesion and
receptor-ligand interactions. We postulate that when the
mutated allele is expressed, the protein lacks the entire
cadherin domain, the five EGF domains, and the LamG
domains (Fig. 3b).
CELRS1 has an ortholog in Drosophila, the flamingo
(Fmi). Fmi is localized at cell–cell boundaries in the wing.
In the absence of Fmi, planar polarity was distorted [27].
In humans and rodents, there are three genes CELSR1–3
and Celsr1–3. Celsr1 and Celsr2 expression is observed
during gastrulation and within the developing nervous
system. Celsr3 transcripts are found only at sites of active
neurogenesis [28] and mutations in CELSR1 are associated
with neural tube defects in humans [29, 30].
Recent biological evidence reported in the literature sup-
ports the causal role of CELSR1 for LE in the family
pedigree. Tatin et al. recently showed that CELSR1 and
VANGL2 play critical roles in the complex morphogenetic
process of intraluminal valve formation in murine lymph-
atic vessels. In their work, they demonstrated that duringvalve leaflet formation, endothelial cells recruit CELSR1
and VANGL2 from filopodia to discrete membrane do-
mains at cell-cell contacts. Furthermore, mouse mutants
Crsh (Celsr1) and Looptail (Vangl2) show valve aplasia [31].
The proband displayed a common lymphatic phenotype
consisting of extensive dermal backflow, tortuous vessels,
as well as unique “sheet-like flow” in both legs indicating a
defect in the valvular mechanism of lymph propulsion in
collecting vessels. While we have not conducted func-
tional studies of the CELSR1 mutation identified in this
family, the phenotype is consistent with the phenotype
described in the mouse mutant Crsh [31].
In this family, the phenotype was not apparent in any
living males, but obviously was passed to daughters
through male parents, both now deceased and not avail-
able for clinical diagnosis or DNA collection. Three living
males in the third and fourth generations were not
reported to have lymphedema, but unfortunately not
available for clinical diagnosis and genotyping. As a result,
we are unable to determine whether penetrance is limited
to females.
Conclusion
This report provides the first evidence that defective
planar cell polarity signaling pathway may participate as
Gonzalez-Garay et al. Vascular Cell  (2016) 8:1 Page 5 of 6the cause of primary, non-syndromic lymphedema in
humans.
Consent
Written informed consent for images contained in this
report was obtained from the patient's parents in accord-
ance with the guidelines of the University of Texas Health
Science Center Institutional Review Board.
Additional files
Additional file 1: Video 1. The abnormal NIRFLI movie of lymphatic
function in the left foot of the proband showing unusual lymph flow
from the dorsal foot injections. (AVI 4088 kb)
Additional file 2: Video 2. The normal NIRFLI movie of lymphatic
function in the left foot of the asymptomatic mother showing typical
lymph flow from the dorsal foot injections within collecting lymphatic
vessels. (AVI 5480 kb)
Additional file 3: Figure S1. A composite picture of two
electropherograms comparing the Sanger sequencing results from two
members of a family with lymphedema. The top panel represents the WT
sequence of an unaffected family member (#152). The low panel represents
the heterozygous mutation in the affected index patient (#143). The validation
was performed as described previously [32] using the following primers:
forward TGAGGTTGGGAGCCGGTAGAGG and reverse GTACCGACAGGGTAT
GTGAAGGCG. (TIF 201 kb)
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